Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 3
2013 7
2014 9
2015 7
2016 11
2017 6
2018 4
2019 3
2020 7
2021 14
2022 16
2023 8
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Results by year

Filters applied: Meta-Analysis, Review, Systematic Review, in the last 10 years. Clear all
Page 1
Selumetinib.
[No authors listed] [No authors listed] 2021 Jan 21. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2021 Jan 21. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 33830716 Free Books & Documents. Review.
Selumetinib is an oral, small molecule inhibitor of the mitogen activated protein kinase 1 and 2 (MEK1/2) that is used to treat symptomatic, refractory fibromas in neurofibromatosis type 1. Selumetinib is associated with transient and usually mild elevations in seru …
Selumetinib is an oral, small molecule inhibitor of the mitogen activated protein kinase 1 and 2 (MEK1/2) that is used to treat sympt …
Selumetinib: First Approval.
Markham A, Keam SJ. Markham A, et al. Drugs. 2020 Jun;80(9):931-937. doi: 10.1007/s40265-020-01331-x. Drugs. 2020. PMID: 32504375 Review.
Selumetinib (KOSELUGO(TM); AZD6244, ARRY-142886) is a mitogen-activated protein kinase 1 and 2 (MEK1/2) inhibitor being developed by AstraZeneca for the treatment of tumours associated with neurofibromatosis and various cancers. ...This article summarizes the milestones in …
Selumetinib (KOSELUGO(TM); AZD6244, ARRY-142886) is a mitogen-activated protein kinase 1 and 2 (MEK1/2) inhibitor being developed by …
A Review of Selumetinib in the Treatment of Neurofibromatosis Type 1-Related Plexiform Neurofibromas.
Anderson MK, Johnson M, Thornburg L, Halford Z. Anderson MK, et al. Ann Pharmacother. 2022 Jun;56(6):716-726. doi: 10.1177/10600280211046298. Epub 2021 Sep 18. Ann Pharmacother. 2022. PMID: 34541874 Review.
Cost and treatment burden must be considered when selecting selumetinib therapy. CONCLUSION: Selumetinib exhibits impressive antitumor activity and sustained clinical benefit in patients lacking other viable treatment options. Further studies are warranted to determ …
Cost and treatment burden must be considered when selecting selumetinib therapy. CONCLUSION: Selumetinib exhibits impressive a …
Selumetinib: a selective MEK1 inhibitor for solid tumor treatment.
Hedayat M, Jafari R, Majidi Zolbanin N. Hedayat M, et al. Clin Exp Med. 2023 Jun;23(2):229-244. doi: 10.1007/s10238-021-00783-z. Epub 2022 Feb 16. Clin Exp Med. 2023. PMID: 35171389 Review.
The efficacy of selumetinib in various solid tumors such as colorectal cancer, lung cancer, neurofibroma, and melanoma is investigated. The present paper provides an overview of the MAPK cascade, the role of selumetinib as a MEK1/2 inhibitor, and the related finding …
The efficacy of selumetinib in various solid tumors such as colorectal cancer, lung cancer, neurofibroma, and melanoma is investigate …
Clinical Pharmacokinetics and Pharmacodynamics of Selumetinib.
Campagne O, Yeo KK, Fangusaro J, Stewart CF. Campagne O, et al. Clin Pharmacokinet. 2021 Mar;60(3):283-303. doi: 10.1007/s40262-020-00967-y. Epub 2020 Dec 23. Clin Pharmacokinet. 2021. PMID: 33354735 Free PMC article. Review.
The pharmacokinetic profiles of selumetinib and its active metabolite N-desmethyl selumetinib have been well characterized in both adults and children. ...The most common side effects associated with selumetinib are dermatologic, gastrointestinal toxicities, …
The pharmacokinetic profiles of selumetinib and its active metabolite N-desmethyl selumetinib have been well characterized in …
Selumetinib in the treatment of non-small-cell lung cancer.
Bernabé R, Patrao A, Carter L, Blackhall F, Dean E. Bernabé R, et al. Future Oncol. 2016 Nov;12(22):2545-2560. doi: 10.2217/fon-2016-0132. Epub 2016 Jul 28. Future Oncol. 2016. PMID: 27467210 Review.
KRAS mutations, prevalent in approximately 30% of patients with non-small-cell lung cancer (NSCLC), result in constitutive activation of the pathway. Selumetinib (AZD6244, ARRY-142886) is a potent and selective inhibitor of MEK1/2 which has demonstrated significant efficac …
KRAS mutations, prevalent in approximately 30% of patients with non-small-cell lung cancer (NSCLC), result in constitutive activation of the …
Selumetinib for the treatment of non-small cell lung cancer.
Casaluce F, Sgambato A, Maione P, Sacco PC, Santabarbara G, Gridelli C. Casaluce F, et al. Expert Opin Investig Drugs. 2017 Aug;26(8):973-984. doi: 10.1080/13543784.2017.1351543. Epub 2017 Jul 12. Expert Opin Investig Drugs. 2017. PMID: 28675058 Review.
Areas covered: A phase II trial in KRAS-mutant NSCLC had shown significant improvements in PFS and ORR in patients treated with selumetinib plus docetaxel compared to docetaxel alone. Disappointing data emerged from the next phase III trial in which the addition of selu …
Areas covered: A phase II trial in KRAS-mutant NSCLC had shown significant improvements in PFS and ORR in patients treated with selumetin …
Selumetinib (Koselugo): CADTH Reimbursement Recommendation: Indication: For the treatment of pediatric patients aged 2 years and above, with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas.
[No authors listed] [No authors listed] Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 May. Report No.: SR0764REC. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 May. Report No.: SR0764REC. PMID: 37643271 Free Books & Documents. Review.
Management of neurofibromatosis type 1-associated plexiform neurofibromas.
Fisher MJ, Blakeley JO, Weiss BD, Dombi E, Ahlawat S, Akshintala S, Belzberg AJ, Bornhorst M, Bredella MA, Cai W, Ferner RE, Gross AM, Harris GJ, Listernick R, Ly I, Martin S, Mautner VF, Salamon JM, Salerno KE, Spinner RJ, Staedtke V, Ullrich NJ, Upadhyaya M, Wolters PL, Yohay K, Widemann BC. Fisher MJ, et al. Neuro Oncol. 2022 Nov 2;24(11):1827-1844. doi: 10.1093/neuonc/noac146. Neuro Oncol. 2022. PMID: 35657359 Free PMC article. Review.
There have been tremendous advances over the past two decades in our understanding of PN, and the recent regulatory approvals of the MEK inhibitor selumetinib are reshaping the landscape for PN management. At present, there is no agreed upon PN definition, diagnostic evalu …
There have been tremendous advances over the past two decades in our understanding of PN, and the recent regulatory approvals of the MEK inh …
72 results